-
Something wrong with this record ?
Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay
A. Jabor, Z. Kubíček, J. Čásenská, T. Vacková, V. Filová, J. Franeková
Status not-indexed Language English Country Netherlands
Document type Journal Article
NLK
Directory of Open Access Journals
from 2015
PubMed Central
from 2015
Open Access Digital Library
from 2015-04-01
ROAD: Directory of Open Access Scholarly Resources
from 2015
- Publication type
- Journal Article MeSH
BACKGROUND: Prothrombin/Protein Induced by Vitamin K Absence-II (PIVKA-II) is a candidate biomarker of hepatocellular cancer, recommended both for diagnostics and monitoring. The aim was to evaluate biological variation (BV) of serum PIVKA-II. METHODS: Within-subject (CVI) and between-subject (CVG) BV estimates were assessed in 14 healthy volunteers in a 6-week protocol. Serum concentrations of PIVKA-II were measured by a Roche Elecsys PIVKA-II diagnostic kit (cobas e8000). Precision (CVA) was assessed from duplicate measurements of all volunteers' samples. Two methods were used for the estimation of CVI: SD-ANOVA and CV-ANOVA method. We calculated the index of individuality (II) and reference change value. The experiment was fully compliant with EFLM database checklist. RESULTS: The CVI of PIVKA-II in healthy persons, as calculated by two statistical methods, were 8.2% (SD-ANOVA with CVA of 3.2%) and 9.4% (CV-ANOVA) with CVA of 2.7%). The CVG was 19.5% (SD-ANOVA), and respective II and RCV were 0.42 and 24.4%. CONCLUSIONS: CVI and CVG of PIVKA-II were 8.2% and 19.5%, respectively, with CVA below 4%. The low II and RCV below 25% enable the use of this biomarker both for diagnostics and monitoring. More data are needed before the introduction of PIVKA-II into clinical practice.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013125
- 003
- CZ-PrNML
- 005
- 20240726151528.0
- 007
- ta
- 008
- 240723e20240319ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.plabm.2024.e00389 $2 doi
- 035 __
- $a (PubMed)38576474
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Jabor, Antonín $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21, Praha 4, Czech Republic $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Praha 10, Czech Republic
- 245 10
- $a Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay / $c A. Jabor, Z. Kubíček, J. Čásenská, T. Vacková, V. Filová, J. Franeková
- 520 9_
- $a BACKGROUND: Prothrombin/Protein Induced by Vitamin K Absence-II (PIVKA-II) is a candidate biomarker of hepatocellular cancer, recommended both for diagnostics and monitoring. The aim was to evaluate biological variation (BV) of serum PIVKA-II. METHODS: Within-subject (CVI) and between-subject (CVG) BV estimates were assessed in 14 healthy volunteers in a 6-week protocol. Serum concentrations of PIVKA-II were measured by a Roche Elecsys PIVKA-II diagnostic kit (cobas e8000). Precision (CVA) was assessed from duplicate measurements of all volunteers' samples. Two methods were used for the estimation of CVI: SD-ANOVA and CV-ANOVA method. We calculated the index of individuality (II) and reference change value. The experiment was fully compliant with EFLM database checklist. RESULTS: The CVI of PIVKA-II in healthy persons, as calculated by two statistical methods, were 8.2% (SD-ANOVA with CVA of 3.2%) and 9.4% (CV-ANOVA) with CVA of 2.7%). The CVG was 19.5% (SD-ANOVA), and respective II and RCV were 0.42 and 24.4%. CONCLUSIONS: CVI and CVG of PIVKA-II were 8.2% and 19.5%, respectively, with CVA below 4%. The low II and RCV below 25% enable the use of this biomarker both for diagnostics and monitoring. More data are needed before the introduction of PIVKA-II into clinical practice.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kubíček, Zdenek $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21, Praha 4, Czech Republic
- 700 1_
- $a Čásenská, Jitka $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21, Praha 4, Czech Republic $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Praha 10, Czech Republic
- 700 1_
- $a Vacková, Tereza $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21, Praha 4, Czech Republic $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Praha 10, Czech Republic
- 700 1_
- $a Filová, Vanda $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21, Praha 4, Czech Republic
- 700 1_
- $a Franeková, Janka $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21, Praha 4, Czech Republic $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Praha 10, Czech Republic
- 773 0_
- $w MED00194320 $t Practical laboratory medicine $x 2352-5517 $g Roč. 39 (20240319), s. e00389
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38576474 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151521 $b ABA008
- 999 __
- $a ok $b bmc $g 2125611 $s 1224988
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 39 $c - $d e00389 $e 20240319 $i 2352-5517 $m Practical laboratory medicine $n Pract Lab Med $x MED00194320
- LZP __
- $a Pubmed-20240723